Bright Minds' Phase 2 DEE epilepsy trial halted as FDA imposes partial clinical hold on BMB-101
The hold, tied to toxicity seen in mice, cut the biotech's share price roughly in half and delays its lead seizure program.
Read at Dealroom →Full coverage · 9 outlets
- Dealroom · lead
- Fierce BiotechFDA dims Bright Minds’ outlook with partial hold on seizure trial over toxicity in mice
- AllSciBright Minds' Phase II DEE seizure trial blocked by FDA partial clinical hold on BMB-101
- scanx.tradeFDA places partial clinical hold on Bright Minds' BMB-101 trial
- GuruFocusFDA Imposes Partial Clinical Hold on Bright Minds Biosciences (D
- Mugglehead Investment MagazineBright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trial
- The Clinical Trial VanguardBright Minds’ BMB-101 Hold Exposes a Recurring Failure in Preclinical-to-IND Translation
- Stock TitanThe FDA put Bright Minds' planned seizure study partly on hold, citing toxicity findings in mice.
- MSNFDA puts partial hold on Bright Minds’ Phase II seizure study